Search details
1.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Article
in English
| MEDLINE | ID: mdl-33538797
2.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Article
in English
| MEDLINE | ID: mdl-32785666
3.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Article
in English
| MEDLINE | ID: mdl-30850381
4.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol
; 158(3): 631-639, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32534811
5.
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
J Pharmacokinet Pharmacodyn
; 44(6): 537-548, 2017 Dec.
Article
in English
| MEDLINE | ID: mdl-28918591
6.
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.
Respir Res
; 17: 29, 2016 Mar 18.
Article
in English
| MEDLINE | ID: mdl-26993628
7.
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
Am J Hematol
; 96(5): E175-E179, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33617672
8.
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Adv Drug Deliv Rev
; 207: 115193, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38311111
9.
Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.
Biopharm Drug Dispos
; 33(4): 207-17, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22498895
10.
A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
J Allergy Clin Immunol
; 138(6): 1730-1732, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27567329
11.
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Adv Ther
; 39(1): 598-618, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34822104
12.
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Adv Ther
; 39(8): 3635-3653, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35708885
13.
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
Clin Drug Investig
; 42(8): 657-668, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35829925
14.
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Clin Cancer Res
; 28(7): 1294-1301, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-34980599
15.
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Clin Pharmacol Ther
; 110(5): 1216-1230, 2021 11.
Article
in English
| MEDLINE | ID: mdl-33899934
16.
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
J Clin Pharmacol
; 60 Suppl 1: S105-S119, 2020 10.
Article
in English
| MEDLINE | ID: mdl-33205423
17.
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
J Clin Pharmacol
; 60 Suppl 1: S120-S131, 2020 10.
Article
in English
| MEDLINE | ID: mdl-33205435
18.
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
MAbs
; 12(1): 1699768, 2020.
Article
in English
| MEDLINE | ID: mdl-31852341
19.
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Clin Cancer Res
; 26(2): 364-372, 2020 01 15.
Article
in English
| MEDLINE | ID: mdl-31540980
20.
Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates.
CPT Pharmacometrics Syst Pharmacol
; 8(8): 606-615, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31207190